THE “PROTOCOL” STUDY: PRELIMINARY RESULTS

QR Code

THE “PROTOCOL” STUDY: PRELIMINARY RESULTS

Aim. To reveal the association of gene polymorphism CYP2С19*2 and recurrent early stent thrombosis in coronary vessels, and paradoxal response to clopidogrel intake in patients — the inhabitants of Siberian Region — after acute coronary syndrome.Material and methods. Totally 105 patients studied, ho...

Full description

Saved in:

Bibliographic Details
Main Authors:	E. M. Zelenskaya, A. I. Subbotovskaya, V. I. Ganyukov, N. A. Kochergin, V. B. Barbarich, N. O. Saraeva, A. V. Vybivantseva, K. A. Apartsin, G. I. Lifshitz
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2015-10-01
Series:	Российский кардиологический журнал
Subjects:	cyp2с19 clopidogrel stent thrombosis paradoxal laboratory reaction residual platelet aggregation
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/315
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

THE PROTOCOL: INFLUENCE OF THE COMBINATION CARRIAGE СУР2С19*2 AND *17 ON EFFICACY OF CLOPIDOGREL
by: Е. М. Zelenskaya, et al.
Published: (2017-11-01)

RESIDUAL PLATELET REACTIVITY DURING THERAPY WITH INHIBITORS OF CYCLOOXIGENASE OR ADENOSINE DIPHOSPHATE RECEPTORS
by: A. A. Lomonosova, et al.
Published: (2015-12-01)

EVALUATION OF PLATELET AGGREGATION IN CLINICAL PRACTICE
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

THERAPEUTIC EQUIVALENCE OF ORIGINAL CLOPIDOGREL (PLAVIX) AND ITS GENERIC (EGITROMB). RESULTS OF COMPARATIVE RANDOMIZED CROSS-OVER BLIND STUDY
by: V. V. Yakusevich, et al.
Published: (2016-01-01)

RESTENOSIS AND IN-STENT STENOSIS: PATHOGENETIC MECHANISMS AND PROGNOSTIC MARKERS
by: G. A. Berezovskaya, et al.
Published: (2012-12-01)

Predictors of angina pain relapse after coronary stenting for acute coronary syndrome in Buryats
by: E. M. Zelenskaya, et al.
Published: (2023-11-01)

Anti-aggregant therapy in patients with coronary heart disease and gastric ulcer
by: A. B. Sumarokov, et al.
Published: (2010-10-01)

Thrombosis prevention in percutaneous coronary interventions
by: V. P. Lupanov, et al.
Published: (2009-08-01)

Clinical and Laboratory Predictors of Major Adverse Cardiac Events in Patients with Ischemic Heart Disease Following Elective Percutaneous Coronary Intervention
by: E. Z. Golukhova, et al.
Published: (2016-11-01)

ANTIPLATELET DRUGS RESISTANCE IN PATIENTS WITH ISCHEMIC HEART DISEASE AND OBLITERATIVE ATHEROSCLEROSIS OF LOWER LIMB ARTERIES ASSOCIATED WITH DIABETES MELLITUS TYPE 2
by: E. V. Gorjacheva, et al.
Published: (2016-01-01)

ANTIPLATELET THERAPY RESISTANCE IN PATIENTS WITH ACUTE CORONARY SYNDROME WITH ST-SEGMENT ELEVATION
by: D. H. Ainetdinova, et al.
Published: (2016-01-01)

GENE CYP2C19 POLYMORPHISM G681A INFLUENCE ON THE EFFICACY OF CLOPIDOGREL IN ENDOVASCULAR TREATMENT OF ISCHEMIC HEART DISEASE COMORBID WITH TYPE 2 DIABETES
by: A. N. Repin, et al.
Published: (2015-10-01)

Preliminary Data from a Study on Polymorphism RS4244285 of P4502c19 Cytochrome Gene in Patients with Acute Coronary Syndrome, Undergoing Treatment with Dual Antiplatelet Therapy With Clopidogrel and Aspirin
by: Katya Kovacheva, et al.
Published: (2016-09-01)

The role of platelets in inflammation and immunity
by: S. P. Sviridova, et al.
Published: (2018-09-01)

High residual platelet aggregation in patients with coronary artery disease: a new methodological approach to detection
by: O. A. Trubacheva, et al.
Published: (2021-07-01)

Antiaggregant influence on platelet aggregation in patients with acute coronary syndrome without ST segment elevation
by: T. M. Poponina, et al.
Published: (2006-10-01)

THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

Role of Tumor Microenvironment in the Risk of Thromboembolic Complications in Ovarian Cancer
by: A. S. Safonov, et al.
Published: (2024-10-01)

Platelet aggregation under the conditions of vortex flow in vitro in patients with chronic heart failure
by: O. A. Trubacheva, et al.
Published: (2022-07-01)

Pharmacogenetic substantiation of personalized prescription of oral anticoagulants in clinical practice
by: K.I. Bentsionova, et al.
Published: (2023-03-01)

Clopidogrel therapy effects on cell hemostasis in acute coronary syndrome
by: R. A. Rakhimova, et al.
Published: (2008-12-01)

Platelet aggregation function test for children in order to determine the normative values in different age groups
by: O. B. Gordeeva, et al.
Published: (2022-04-01)

How real is a threat of late thrombosis for drug-eluting stents? Stent comparison and focus on everolimus
by: V. P. Lupanov, et al.
Published: (2009-10-01)

Comprehensive Approach to Developing Baseline Reference Ranges for Platelet Function
by: Olga B. Gordeeva, et al.
Published: (2023-05-01)

Clopidogrel effectiveness in patients with ST elevation myocardial infarction
by: O. V. Sirotkina, et al.
Published: (2009-02-01)

MOLECULAR-GENETIC APPROACH FOR OPTIMIZATION OF MODERN ANTIAGGREGANT THERAPY
by: N. YU. Knauer, et al.
Published: (2012-04-01)

ASSOCIATION OF THE GENE CYP11B2 WITH THE RISK OF ESSENTIAL HYPERTENSION AND ATHEROTHROMBOTIC COMPLICATIONS
by: E. M. Zelenskaya, et al.
Published: (2016-06-01)

PLATELET FUNCTION TEST FOR THE ASSESSMENT OF THROMBOSIS AND BLEEDING RISK IN CHD PATIENTS TAKING ANTIPLATELET MEDICATIONS
by: A. L. Komarov, et al.
Published: (2015-03-01)

ACC/AHA CLOPIDOGREL CLINICAL ALERT. WHAT MUST BE MODERN ANTIPLATELET THERAPY?
by: S. J. Martsevich
Published: (2016-01-01)

ANTIAGGREGANT THERAPY AND REDUCTION OF HIGH RESIDUAL PLATELET REACTIVITY
by: N. A. Mazur, et al.
Published: (2012-08-01)

CLOPIDOGREL RESPONSE IN ACUTE CORONARY SYNDROME PATIENTS WITH CYP2Y12*2 AND CYP2Y12*3 POLYMORPHISMS
by: R. Rahmatini, et al.
Published: (2018-04-01)

CLOPIDOGREL PHARMACOGENETICS
by: A. N. Meshkov
Published: (2016-01-01)

CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE
by: A. I. Akhmetova, et al.
Published: (2017-12-01)

Aspirin vs. P2Y12 Inhibitor Rivalry: Which One Can be Continued During Gastrointestinal Bleeding
by: Muhammad Begawan Bestari, et al.
Published: (2019-11-01)

Aspirin vs. P2Y12 Inhibitor Rivalry: Which One Can be Continued During Gastrointestinal Bleeding
by: Muhammad Begawan Bestari, et al.
Published: (2019-11-01)

A PCR-lateral flow assay system based on gold magnetic nanoparticles for CYP2C19 genotyping and its clinical applications
by: Yan Xuhong, et al.
Published: (2019-12-01)

Morphological determinants for the local hemostatic effect of exogenous fibrin monomer in its systemic administration after injury with inhibition of platelet aggregation in the experiment
by: V. M. Vdovin, et al.
Published: (2023-10-01)

Platelet activation and red blood cell changes in thrombotic and rheological disturbances among coronary heart disease patients
by: T. E. Shirokova, et al.
Published: (2007-10-01)

Endovascular Stent Thrombectomy in Patients With Acute Lower Limb Arterial Thrombosis on the Background of COVID-19
by: I. S. Semyin, et al.
Published: (2023-04-01)

Regional aspects of associations of the CYP2C19 gene polymorphism with coronary atherosclerosis in acute coronary syndrome
by: K. Yu. Nikolaev, et al.
Published: (2018-11-01)